We have located links that may give you full text access.
Acute renal failure in an AIDS patient on tenofovir: a case report.
Journal of Medical Case Reports 2008 March 32
INTRODUCTION: Tenofovir is a potent nucleotide analogue reverse-transcriptase inhibitor used with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV) infection. Despite the absence of renal toxicity observed in the major clinical trials of tenofovir, several case reports of acute renal failure (ARF) and proximal tubule dysfunction have been described.
CASE PRESENTATION: We report a patient who developed ARF and Fanconi syndrome during treatment with tenofovir. Despite severe metabolic acidosis associated with a creatinine of 9.8 mg/dL (866 mumol/L), this patient's condition improved on discontinuation of tenofovir treatment without requiring renal replacement therapy.
CONCLUSION: Vigilant screening of kidney function is required regularly after initiation of tenofovir due to possible appearance of renal failure.
CASE PRESENTATION: We report a patient who developed ARF and Fanconi syndrome during treatment with tenofovir. Despite severe metabolic acidosis associated with a creatinine of 9.8 mg/dL (866 mumol/L), this patient's condition improved on discontinuation of tenofovir treatment without requiring renal replacement therapy.
CONCLUSION: Vigilant screening of kidney function is required regularly after initiation of tenofovir due to possible appearance of renal failure.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app